Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3

Immunology Letters

Volumn 131, Issue 2, 2010, Pages 126-130

  Brayer, Jason ^a   Cheng, Fengdong ^a   Wang, Hongwei ^a   Horna, Pedro ^a   Vicente Suarez, Ildefonso ^a   Pinilla Ibarz, Javier ^a   Sotomayor, Eduardo M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

CD8; Cytotoxic; STAT3

Indexed keywords

GAMMA INTERFERON; STAT3 PROTEIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; CANCER VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; IN VITRO STUDY; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CELL PROLIFERATION; CYTOTOXICITY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; MACROPHAGE; METABOLISM; PATHOLOGY; SECRETION (PROCESS); TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CROSS-PRIMING; CYTOTOXICITY, IMMUNOLOGIC; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953708336     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.03.004     Document Type: Article

References (24)

1. Morgan D.J., Kurts C., Kreuwel H.T.C., Holst K.L., Heath W.R., Sherman L.A. Ontogeny of T cell tolerance to peripherally expressed antigens. PNAS 1999, 96:3854-3858.
2. Kurts C., Kosaka H., Carbone F.R., Miller J.F.A.P., Heath W.R. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8+ T cells. J Exp Med 1997, 186(2):239-245.
3. Vezys V., Olson S., Lefrancois L. Expression of intestine-specific antigen reveals novel pathways of CD8 T cell tolerance induction. Immunity 2000, 12:505-514.
4. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999, 5:677-685.
5. Janicki C.N., Jenkinson S.R., Williams N.A., Morgan D.L. Loss of high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res 2008, 68:2993-3000.
6. Zippelius A., Batard P., Rubio-Godoy V., Lienard D., Lejeune F., et al. Effector function of tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004, 64:2865-2873.
7. Ohlen C., Kalps M., Cheng L.E., Shur A.C., Hong D.J., Carson B.D., et al. CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J Exp Med 2002, 195(11):1407-1418.
8. Frey A.B., Monu N. Effector phase tolerance: another mechanism of how cancer escapes antitumor immune response. J Leukoc Biol 2006, 79:652-662.
9. Dumortier H., van Mierlo G.J.D., Egan D., van Ewijk W., Toes R., Offringa R., et al. Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates a CD8+ central memory-like T cells that can be rescued for full effector function. J Immunol 2005, 175:855-863.
10. Bai A., Higham E., Eisen H.N., Wittrup K.D., Chen J. Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. PNAS 2008, 105:13003-13008.
11. Rosenberg S.A., Sherry R.M., Morton K.E., Scharfman W.J., Yang J.C., Topalian S.L., et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005, 175:6169-6176.
12. Norian L.A., Rodriguez P.C., O'Mara L.A., Zabaleta J., Ochoa A.C., Cella M., et al. Tumor-infltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res 2009, 69(7):3086-3094.
13. Munn D.H., Sharma M.D., Lee J.R., Jhaver K.G., Johnson T.S., Keskin D.B., et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002, 297:1867-1870.
14. Talmadge J.E. Pathways mediating the expression and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007, 13(18):5243-5248.
15. Takeda K., Clausen B.E., Kaisho T., Tsujimura T., Terada N., Forster I., et al. Th1 activity and development of chronic enterocolitis in mice devoid of STAT3 in macrophages and neutrophils. Immunity 1999, 10:39-49.
16. Cheng F., Wang H.W., Cuenca A., Huang M., Ghansah T., Brayer J., et al. Critical role for STAT3 signaling in immune tolerance. Immunity 2003, 19(3):425-436.
17. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. PNAS 1998, 95(3):1178-1183.
18. Albert M.L., Pearce S.F., Francisco L.M., Sauter B., Roy P., Silverstein R.L., et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36 and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998, 188(7):1359-1368.
19. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007, 25:267-296.
20. Toes R.E., Offringa R., Blom R.J., Melief C.J., Kast W.M. Peptide vaccination can lead to tumor growth through specific T-cell tolerance induction. PNAS 1996, 93(13):7855-7860.
21. Koniaras C., Bennett S.R., Carbone F.R., Heath W.R., Lew A.M. Peptide-induced deletion of CD8 T cells in vivo via apoptosis in situ. Int Immunol 1997, 9:1601-1605.
22. Finbloom D.S., Winestock K.D. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol 1995, 155(3):1079-1090.
23. Ohm J.E., Carbone D.P. VEGF as a mediator of tumor associated immunodeficiency. Immunol Res 2001, 23:263-272.
24. Manning E.A., Ullman J.G.M., Leatherman J.M., Asquith J.M., Hansen T.R., Armstrong T.D., et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 2007, 13(13):3951-3959.